Possible distribution or partnerships/ takeovers (Hypothetical only), page-118

Your right Vlado, The Bard1 gene itself is not our patient(s). I posted as it does mean that Thermo Fisher is directly involved with and very familiar with the Bard1 gene. I felt and think this makes them more likely to able to assist us with the assay test development.

They are directly involved in billions US$ of sales of pathology test products. Thermo Fishers has a large established distribution channel and the acquisition link showed they are also aggressively expanding into areas directly aligned with our target medical markets. This  means they have a very good insight on the value and volume sales of the BD1 commercial tests and value of our patents. All of which support my comfort level with my now over weight position in BD1.